Skip to main content
Clinical Trials/IRCT20181109041596N1
IRCT20181109041596N1
Recruiting
Phase 3

Evaluation of effect of fluoxetine on the clinical prognosis in patients with anterior ischemic optic neuropathy (AION) according to evaluations of visual acuity and VEP tests as main outcomes, in comparison between drug and placebo groups.

Iran University of Medical Sciences0 sites100 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Iran University of Medical Sciences
Enrollment
100
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Iranian patients
  • Age over 18 years old
  • Patients with diagnosis of AION; non\-arteritic type

Exclusion Criteria

  • Pregnancy before or during study
  • Past medical history of cataract, glaucoma ( open or close angle ) congenital eye disease such as cloboma and involvement with disease effecting the central visual field of patient
  • Patients with past medication history of using fluoxetine or other psychological medications including antidepressants
  • Patients suffering from psychological disease
  • Patients who use medications including :arthemeter? astemizol, cisapride, eliglustat, goserelin, isocarboxazide, artemether, leuprolide, linezolid, lumefantrine, methylene blue, phenelzine, pimozide, procarbazine, selegiline, thioridazine, tranylcypromine
  • Patients diagnosed with immunologic and collagen vascular disease
  • Patients with symptoms of or diagnosed with giant cell arteritis and positive CRP more than 3\+ or ESR more than 40
  • Trauma or surgery history of eyes
  • Duration between involvement and interview more than 3 weeks
  • Patients without compliance of using fluoxetine or disagrement of patient to continue accompanying the study

Outcomes

Primary Outcomes

Not specified

Similar Trials